Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

Role of Transforming Growth Factor β in Human Disease

Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,430 · see citing works

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154 · see citing works

Idiopathic Pulmonary Fibrosis

Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056 · see citing works

Cellular senescence mediates fibrotic pulmonary disease

Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · cited 1× · see citing works

Targeting the TGFβ signalling pathway in disease

Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · see citing works

Mucins in cancer: function, prognosis and therapy

Kufe, D. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2761 · Cited by 1,397 · see citing works

Pirfenidone in idiopathic pulmonary fibrosis

Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 957 · see citing works

Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 953 · see citing works

Mechanisms of Pulmonary Fibrosis

Thannickal, V. J., Toews, G. B., White, E. S., Lynch, J. P., & Martínez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 806 · see citing works

Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–

Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 802 · see citing works

Structure and Function of the Cell Surface (Tethered) Mucins

Hattrup, C. L., & Gendler, S. J. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100659 · Cited by 781 · see citing works

Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3

MacKinnon, A. C., Gibbons, M., Farnworth, S. L., Leffler, H., Nilsson, U. J., Delaine, T., Simpson, A. J., Forbes, S. J., Hirani, N., Gauldie, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201106-0965oc · Cited by 520 · see citing works

Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells

Carlson, M. E., Hsu, M., & Conboy, I. M. (2008) · Nature · doi:10.1038/nature07034 · Cited by 483 · see citing works

Revealing the Pathogenic and Aging-related Mechanisms of the Enigmatic Idiopathic Pulmonary Fibrosis. An Integral Model

Selman, M., & Pardo, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2221pp · Cited by 456 · see citing works

Antifibrotic activities of pirfenidone in animal models

Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · see citing works

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 434 · see citing works

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases

Ishikawa, N., Hattori, N., Yokoyama, A., & Kohno, N. (2012) · Respiratory Investigation · doi:10.1016/j.resinv.2012.02.001 · Cited by 405 · see citing works

Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis <i>ex vivo</i>

Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02367-2016 · Cited by 403 · see citing works

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · see citing works

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

Bafna, S., Kaur, S., & Batra, S. K. (2010) · Oncogene · doi:10.1038/onc.2010.87 · Cited by 360 · see citing works

IPF lung fibroblasts have a senescent phenotype

Álvarez, D., Cárdenes, N., Sellarés, J., Bueno, M., Corey, C., Hanumanthu, V. S., Peng, Y., D’Cunha, H., Sembrat, J., Nouraie, M., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00220.2017 · Cited by 342 · see citing works

Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs?

Selman, M., Pardo, A., & Kaminski, N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050062 · Cited by 334 · see citing works

Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells

Minagawa, S., Araya, J., Numata, T., Nojiri, S., Hara, H., Yumino, Y., Kawaishi, M., Odaka, M., Morikawa, T., Nishimura, S. L., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00097.2010 · Cited by 323 · see citing works

Cellular interactions in the pathogenesis of interstitial lung diseases

Bagnato, G., & Harari, S. A. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277 · see citing works

Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer

van Putten, J. P. M., & Strijbis, K. (2017) · Journal of Innate Immunity · doi:10.1159/000453594 · Cited by 270 · see citing works

TGF-β and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis

Bonniaud, P., Margetts, P. J., Ask, K., Flanders, K., Gauldie, J., & Kolb, M. R. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5390 · Cited by 252 · see citing works

MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

Huang, L. H., Chen, D., Liu, D. H., Li, Y., Kharbanda, S. M., & Kufe, D. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2474 · Cited by 230 · see citing works

Novel therapeutic approaches for pulmonary fibrosis

Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 203 · see citing works

‘WNT-er is coming’: WNT signalling in chronic lung diseases

Baarsma, H. A., & Königshoff, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209753 · Cited by 179 · see citing works

Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition

Milara, J., Navarro, R., Juan, G., Peiró, T., Serrano, A., Ramón, M., Morcillo, E. J., & Cortijo, J. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200026 · Cited by 171 · see citing works

Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis

Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Burgess, J. K., Mutsaers, S. E., Prêle, C. M., Schuliga, M. J., Grainge, C., & Knight, D. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2018 · Cited by 167 · see citing works

PAI-1 Regulation of TGF-β1–induced Alveolar Type II Cell Senescence, SASP Secretion, and SASP-mediated Activation of Alveolar Macrophages

Rana, T., Jiang, C., Liu, G., Miyata, T., Antony, V. B., Thannickal, V. J., & Liu, R.-M. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0071oc · Cited by 159 · see citing works

Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells

Hisatomi, K., Mukae, H., Sakamoto, N., Ishimatsu, Y., Kakugawa, T., Hara, S., Fujita, H., Nakamichi, S., Oku, H., Urata, Y., et al. (2012) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-12-24 · Cited by 144 · see citing works

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells

Mata, M. (2005) · Thorax · doi:10.1136/thx.2004.025692 · Cited by 137 · see citing works

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis

Lehmann, M., Buhl, L., Alsafadi, H. N., Klee, S., Hermann, S., Mutze, K., Ota, C., Lindner, M., Behr, J., Hilgendorff, A., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0876-y · Cited by 136 · see citing works

Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis

Wakamatsu, K., Nagata, N., Kumazoe, H., Oda, K., Ishimoto, H., Yoshimi, M., Takata, S., Hamada, M., Koreeda, Y., Takakura, K., et al. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.09.003 · Cited by 119 · see citing works

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

Mediavilla-Varela, M., Boateng, K. A., Noyes, D. R., & Antonia, S. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2162-z · Cited by 118 · see citing works

Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon’s Fibroblasts In Vitro

Lin, X., Yu, M., Wu, K., Yuan, H., & Zhong, H. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2815 · Cited by 115 · see citing works

FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis

Penke, L. R. K., Speth, J. M., Dommeti, V. L., White, E. S., Bergin, I. L., & Peters-Golden, M. L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci87631 · Cited by 114 · see citing works

Pirfenidone suppresses MAPK signalling pathway to reverse epithelial‐mesenchymal transition and renal fibrosis

Li, Z., Liu, X., Wang, B., Nie, Y., Wen, J., Wang, Q., & Gu, C. (2016) · Nephrology · doi:10.1111/nep.12831 · Cited by 113 · see citing works

Potent antioxidant role of Pirfenidone in experimental cirrhosis

Salazar-Montes, A., Ruiz-Corro, L., López-Reyes, A. G., Castrejón-Gómez, E., & Armendáriz‐Borunda, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.110 · Cited by 98 · see citing works

Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.

Choi, K., Lee, K., Ryu, S., Im, M.-J., Kook, K. H., & Choi, C. (2012) · PubMed Central · Cited by 88 · see citing works

Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model

Guo, J., Yang, Z., Jia, Q., Bo, C., Shao, H., & Zhang, Z. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.10.019 · Cited by 88 · see citing works

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF

Behrens, M. E., Grandgenett, P. M., Bailey, J. M., Singh, P. K., Yi, C.-H., Yu, F., & Hollingsworth, M. A. (2010) · Oncogene · doi:10.1038/onc.2010.327 · Cited by 81 · see citing works

Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone

Miura, Y., Saito, T., Tanaka, T., Takoi, H., Yatagai, Y., Inomata, M., Nei, T., Saito, Y., Gemma, A., & Azuma, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.09.007 · Cited by 80 · see citing works

WNT Signaling in Lung Aging and Disease

Lehmann, M., Baarsma, H. A., & Königshoff, M. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201608-586aw · Cited by 70 · see citing works

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Fabrellas, E. F., Sánchez, R. P., Abad, C. S., & Samper, G. J. (2018) · Medical Sciences · doi:10.3390/medsci6020051 · Cited by 69 · see citing works

The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane‐tethered mucins

Palmai‐Pallag, T., Khodabukus, N., Kinarsky, L., Leir, S., Sherman, S., Hollingsworth, M. A., & Harris, A. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04711.x · Cited by 65 · see citing works

Superoxide scavenging activity of pirfenidone–iron complex

Mitani, Y., Sato, K., Muramoto, Y., Karakawa, T., Kitamado, M., Iwanaga, T., Nabeshima, T., Maruyama, K., Nakagawa, K., Ishida, K., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.093 · Cited by 65 · see citing works

Aclidinium inhibits human lung fibroblast to myofibroblast transition

Milara, J., Serrano, A., Peiró, T., Gavaldà, A., Miralpeix, M., Morcillo, E. J., & Cortijo, J. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200376 · Cited by 65 · see citing works

Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy

Mori, Y., Akita, K., Yashiro, M., Sawada, T., Hirakawa, K., Murata, T., & Nakada, H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651489 · Cited by 58 · see citing works

Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis

Bellaye, P., & Kolb, M. R. J. (2015) · BMC Medicine · doi:10.1186/s12916-015-0412-6 · Cited by 58 · see citing works

Pirfenidone Inhibits Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway

Zou, W., Huang, Z. L., Jiang, T., Shen, Y., Zhao, A., Zhou, S., & Zhang, S. (2017) · Medical Science Monitor · doi:10.12659/msm.907891 · Cited by 42 · see citing works

Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma

Kurimoto, R., Ebata, T., Iwasawa, S., Ishiwata, T., Tada, Y., Tatsumi, K., & Takiguchi, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6188 · Cited by 38 · see citing works

MUC1 intracellular bioactivation mediates lung fibrosis

Milara, J., Ballester, B., Montero, P., Escrivá, J., Artigues, E., Almiñana, M. A., Pastor-Clerigues, A., Morcillo, E. J., & Cortijo, J. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212735 · Cited by 38 · see citing works

Airway Myofibroblasts and Their Relationship with Airway Myocytes and Fibroblasts

Singh, S. R., & Hall, I. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200706-070vs · Cited by 37 · see citing works

Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer

Fujiwara, A., Shintani, Y., Funaki, S., Kawamura, T., Kimura, T., Minami, M., & Okumura, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.006 · Cited by 37 · see citing works

Transforming growth factor‐β activates c‐Myc to promote palatal growth

Zhu, X., Öztürk, F., Liu, C.-C., Oakley, G. G., & Nawshad, A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24184 · Cited by 28 · see citing works

Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib

Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J. (2018) · Histopathology · doi:10.1111/his.13745 · Cited by 26 · see citing works

Breast Cancer Metastasis: Mechanisms and Therapeutic Implications

Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 420 · see citing works

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Nambiar, A., Kellogg, D., Justice, J., Goros, M., Gelfond, J., Pascual, R., Hashmi, S., Masternak, M., Prata, L., LeBrasseur, N., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104481 · Cited by 298 · see citing works

Fibroblast Senescence in Idiopathic Pulmonary Fibrosis

Lin, Y., & Xu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593283 · Cited by 104 · see citing works

Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients

Giacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 75 · see citing works

Ferroptosis-Related Genes in Bronchoalveolar Lavage Fluid Serves as Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis

Li, M., Wang, K., Zhang, Y., Fan, M., Li, A., Zhou, J.-J., Yang, T., Shi, P.-Y., Li, D.-L., Zhang, G.-J., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.693959 · Cited by 37 · see citing works

Therapeutic Effect of Neuraminidase-1–Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis

Luzina, I. G., Lillehoj, E. P., Lockatell, V., Hyun, S. W., Lugkey, K. N., Imamura, A., Ishida, H., Cairo, C. W., Atamas, S. P., & Goldblum, S. E. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000223 · Cited by 35 · see citing works

Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond

Lillehoj, E. P., Luzina, I. G., & Atamas, S. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883079 · Cited by 33 · see citing works

Novel Synthetic Polymer-Based 3D Contraction Assay: A Versatile Preclinical Research Platform for Fibrosis

Kumari, J., Wagener, F. A. D. T. G., & Kouwer, P. H. J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02549 · Cited by 32 · see citing works

Understanding idiopathic pulmonary fibrosis - Clinical features, molecular mechanism and therapies

Suri, G. S., Kaur, G., Jha, C. K., & Tiwari, M. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111473 · Cited by 28 · see citing works

Recent advances and molecular mechanisms of TGF-β signaling in colorectal cancer, with focus on bioactive compounds targeting

Bakrim, S., Hachlafi, N. E., Khalid, A., Abdalla, A. N., Omari, N. E., Aboulaghras, S., Sakran, A. M. E. A., Goh, K. W., Ming, L. C., Razi, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116886 · Cited by 24 · see citing works

Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives

Hall, I. F., Aikawa, E. R., Sluimer, J. C., Baker, A. H., & Kovacic, J. C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf670 · Cited by 20 · see citing works

Stimuli-Specific Senescence of Primary Human Lung Fibroblasts Modulates Alveolar Stem Cell Function

Melo-Narváez, M. C., Bramey, N., See, F., Heinzelmann, K., Ballester, B., Steinchen, C., Jain, E., Federl, K., Hu, Q., Dhakad, D., et al. (2024) · Cells · doi:10.3390/cells13131129 · Cited by 18 · see citing works

Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art

Paliogiannis, P., Fois, S. S., Fois, A. G., Cossu, A., Palmieri, G., & Pintus, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200730173748 · Cited by 18 · see citing works

Pentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice

Lin, Y., Xu, Z., Zhou, B., Ma, K., & Jiang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.848263 · Cited by 16 · see citing works

Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer

Koltai, T., Reshkin, S. J., Carvalho, T. M. A., & Cardone, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083953 · Cited by 15 · see citing works

Cinnamic acid mitigates methotrexate-induced lung fibrosis in rats: comparative study with pirfenidone

Abdalhameid, E., El-Haleim, E. A. A., Abdelsalam, R. M., Georgy, G. S., Fawzy, H. M., & Kenawy, S. A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02652-w · Cited by 14 · see citing works

Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis

Young, O. N., Bourke, J. E., & Widdop, R. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115839 · Cited by 14 · see citing works

Pirfenidone and nintedanib attenuates pulmonary artery endothelial and smooth muscle cells transformations induced by IL-11

Roger, I., Montero, P., Milara, J., & Cortijo, J. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176547 · Cited by 13 · see citing works

Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs

Wilson, A. C., Chiles, J. W., Ashish, S. Y., Chanda, D., Kumar, P. L., Mobley, J. A., Neptune, E., Thannickal, V. J., & McDonald, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07151-1 · Cited by 12 · see citing works

Current Status of Research on Losartan in Tumour Therapy

Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11 · see citing works

Phosphodiesterase type 10A inhibitor attenuates lung fibrosis by targeting myofibroblast activation

Li, Y., Shi, J., Li, S.-C., Wang, L., Dhar, R., Li, N., Cao, X.-W., Li, Z., & Tang, H. (2023) · iScience · doi:10.1016/j.isci.2023.106586 · Cited by 11 · see citing works

Pirfenidone as a Cornerstone in the Management of Fibrotic Interstitial Lung Diseases and Its Emerging Applications: A Comprehensive Review

Babariya, H., Gaidhane, S., Acharya, S., & Kumar, S. (2024) · Cureus · doi:10.7759/cureus.70497 · Cited by 10 · see citing works

Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells

Merino, A. M., Hoogduijn, M. J., Molina‐Molina, M., Arias‐Salgado, E. G., Korevaar, S. S., Baan, C. C., & Montes‐Worboys, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248415 · Cited by 8 · see citing works

Ugonin L ameliorates pulmonary fibrosis as a novel TβRs inhibitor by regulating the TGF-β/TβRs signaling and autophagy

Hsia, T.-L., Chiou, W.-C., Huang, H., Liu, H., Chen, J., Fu, P., & Huang, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118267 · Cited by 7 · see citing works

Pulmonary delivery of a recombinant RAGE antagonist peptide derived from high-mobility group box-1 in a bleomycin-induced pulmonary fibrosis animal model

Piao, C., Zhuang, C., Ko, M. K., Hwang, D. W., & Lee, M. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2069781 · Cited by 7 · see citing works

Nanoapproach targeting TGFβ1-Smad pathway and modulating lung microenvironment

Kulshrestha, R., Singh, A. K., Kumar, P., Nair, D. S., Batra, J., Mishra, A., & Dinda, A. K. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.06.027 · Cited by 6 · see citing works

Comparative effects of extracellular vesicles and liposomal nanocarriers on bleomycin-induced stress in A549 human adenocarcinoma cells

Conlon, T., Schaaf, M., Mateos‐Maroto, A., Picciotto, S., Morsbach, S., Adamo, G., Si, S., Lieberwirth, I., Rosenauer, C., Landfester, K., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118081 · Cited by 6 · see citing works

Pharmacological frontiers in senescence: Transforming senescence with drug repurposing

Shahzadi, A., Özyazgan, S., & Çakatay, U. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.010 · Cited by 5 · see citing works

Pirfenidone Is a Vasodilator: Involvement of KV7 Channels in the Effect on Endothelium-Dependent Vasodilatation in Type-2 Diabetic Mice

Beck, L., Pinilla, E., Arcanjo, D. D. R., Hernanz, R., Prat‐Duran, J., Petersen, A. G., Köhler, R., Sheykhzade, M., Comerma-Steffensen, S., & Simonsen, U. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.619152 · Cited by 5 · see citing works

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial

Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4 · see citing works

The updated evidence of pirfenidone treated silicosis based on network pharmacology, molecular docking and experimental validation

Chang, S., Wen, S., Zhang, W., Zhang, H.-F., Guo, Y. M., Wang, Q., Hu, X., Liu, Z., Sun, Y., & Yang, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1573241 · Cited by 3 · see citing works

Drug-loaded electrospun fibers with stabilizing sheath: prevent post-fabrication drug precipitation-induced recrystallization and controlling Molecular Relaxation for controlled release

Liu, J., Hou, Y., Yang, Y., Wang, B., Zhang, X., Tian, Y., Wu, G., Gu, B., Ni, Z., & Zhao, G. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107812 · Cited by 2 · see citing works

3D alveolar organoid drug screening model for targeting TGF-β1 in pulmonary fibrosis

Han, H., & Kim, H. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102191 · Cited by 2 · see citing works

Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis

Young, O. N., Widdop, R. E., & Bourke, J. E. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2616755 · Cited by 1 · see citing works

Primary human lung fibroblasts exhibit trigger- but not disease-specific cellular senescence and impair alveolar epithelial cell progenitor functionPreprint

Bramey, N., Melo-Narváez, M. C., See, F., Ballester-Lllobell, B., Steinchen, C., Jain, E., Hafner, K., Yildirim, A. Ö., Königshoff, M., & Lehmann, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.24.550385 · Cited by 1 · see citing works

Stimuli-specific senescence of primary human lung fibroblasts modulates alveolar stem cell functionPreprint

Bramey, N., Melo-Narváez, M. C., See, F., Ballester-Lllobell, B., Steinchen, C., Jain, E., Hafner, K., Yildirim, A. Ö., Königshoff, M., & Lehmann, M. (2024) · Research Square · doi:10.21203/rs.3.rs-3879423/v1 · Cited by 1 · see citing works

Modeling Molecular Mechanisms of Pirfenidone Interaction with KinasesPreprint

Wijewardhane, P. R., Wells, A. R., Muhoberac, M., Leung, K. P., & Chopra, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.22.586235 · Cited by 1 · see citing works

Sustained Release of Antifibrotic Nintedanib from Polymer Microparticles Reduces Dosing Frequency While Reducing Inflammation in Murine Idiopathic Pulmonary Fibrosis

Opolot, E. E., Goshevski, F., Chaudhary, R., Kilgore, J. A., Williams, N. S., von Recum, H. A., & Desai, A. B. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03729-8

Biodegradable Nanoparticle-in-Implant Platform for Sustained and Light-Boosted Pirfenidone DeliveryPreprint

Mwaniki, J., Kelley, J., & Park, Y. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.17.732517

Cyclin-dependent kinases as signaling integrators in cancer: Structural evolution, functional plasticity, and drug discovery

Upadhyay, S., Khan, S., Bhardwaj, M., & Hassan, M. I. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168364

A bioflavonoid Rutin ameliorates chronic radiation-induced lung fibrosis through predicted interaction with TGF-βRI/II and modulation of TGF-β/Smad signaling in a mouse model

Verma, S., Mehta, D., Kumar, S., Verma, Y. K., & Kalra, N. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100528

Prophylactic pirfenidone to prevent radiation- induced lung injury in ICI-pretreated lung cancer patients: a phase II study

Huang, Y., Ma, J., Han, G., Jianping, B., Pi, G., Li, Y., Peng, Y., Xiao, C., & Tuo, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1876642

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1

Jin, J., Togo, S., Kadoya, K., Tulafu, M., Namba, Y., Iwai, M., Watanabe, J. A., Nagahama, K. Y., Okabe, T., Hidayat, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1093-z · Cited by 127 · see citing works

Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo

Ma, Z., Zhao, C., Chen, Q., Yu, C.-H., Zhang, H., Zhang, Z., Huang, W., & Shen, Z. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.10.006 · Cited by 30 · see citing works

Molecular mechanisms of pirfenidone activity in human lung fibroblasts

Conte, E., Fruciano, M., Gili, E., Fagone, E., Iemmolo, M., & Vancheri, C. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.p825 · Cited by 4 · see citing works

Effect of pirfenidone on TGF-β-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis

Hostettler, K., Zhong, J., Tamm, M., Lardinois, D., & Roth, M. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.p763 · Cited by 6 · see citing works

Role of MUC1 in idiopathic pulmonary fibrosis: mechanistic insights

Ballester, B., Roger, I., Contreras, S., Montero, P., & Milara, J. (2017) · European Respiratory Journal · doi:10.1183/1393003.congress-2017.pa4889 · Cited by 2 · see citing works